Please ensure Javascript is enabled for purposes of website accessibility

ChemoCentryx Floats Common Stock Issue

By Eric Volkman - Apr 15, 2013 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage pharmaceutical company will sell $60 million worth of shares.

ChemoCentryx (CCXI 3.36%) is set to raise up to $60 million in a new public offering of its common stock. The company also intends to grant its underwriters a 30-day purchase option for an additional $9 million worth of shares to cover over-allotments, if any.

The issue has commenced, although the company added that "there can be no assurance as to whether or when the offering may be completed."

ChemoCentryx said it plans to use the proceeds "to fund development of our drug candidates, for working capital and other general corporate purposes."

JPMorgan Chase unit J.P. Morgan Securities and Goldman Sachs are the joint book-running managers of the offering.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ChemoCentryx, Inc. Stock Quote
ChemoCentryx, Inc.
$22.79 (3.36%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.